A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Trial Profile

A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary)
  • Indications Meningioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 06 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jun 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top